In vitro permeability of peptidomimetic drugs: The role of polarized efflux pathways as additional barriers to absorption

Advanced Drug Delivery Reviews

Volumn 23, Issue 1-3, 1997, Pages 143-156

  Burton, Philip S ^a   Goodwin, Jay T ^a   Conradi, Robert A ^a   Ho, Norman F H ^a   Hilgers, Allen R ^a  

^a PFIZER INC   (United States)

Author keywords

absorption; blood brain barrier; intestinal mucosa; mechanism; P glycoprotein; permeability; polarized efflux

Indexed keywords

AMINO ACIDS; CELLS; DRUG INTERACTIONS; DRUG THERAPY; METABOLISM; PROTEINS; TISSUE;

BLOOD BRAIN BARRIER; GLYCOPROTEIN; IN VITRO PERMEABILITY; INTESTINAL MUCOSA; PEPTIDOMIMETIC DRUGS; POLARIZED EFFLUX;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; GLYCOPROTEIN P; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; VERAPAMIL;

BLOOD BRAIN BARRIER; CELL SECRETION; DRUG TRANSPORT; ENDOTHELIUM CELL; HUMAN; HYDROPHOBICITY; INTESTINE ABSORPTION; INTESTINE MUCOSA; KIDNEY; LIVER; NONHUMAN; PERMEABILITY BARRIER; POLARIZATION; PRIORITY JOURNAL; REVIEW;

EID: 0031023675     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00432-2     Document Type: Review

References (114)

1. Schultz, S.G. (1976) Transport across epithelia: some basic principles. Kidney Int. 9, 65-75.
2. Stein, W.D. (1990) Channels, Carriers, and Pumps: An Introduction to Membrane Transport. Academic Press, San Diego, CA.
3. Jackson, M.J. (1987) Drug transport across gastrointestinal epithelia. In: L.R. Johnson (Ed.), Physiology of the Gastrointestinal Tract, Raven Press, New York, pp. 1597-1621.
4. Nellans, H.N. (1991) Paracellular intestinal transport: modulation of absorption. Adv. Drug Deliv. Rev. 7, 339-364.
5. Burton, P.S., Conradi, R.A. and Hilgers, A.R. (1991) Transcellular mechanism of peptide and protein absorption: passive aspects. Adv. Drug. Deliv. Rev. 7, 365-386.
6. Banks, W.A., Kastin, A.J., Fischman, A.J., Coy, D.H. and Strauss, S.L. (1986) Carrier-mediated transport of enkaphalins and N-Tyr-MIF-1 across the blood-brain barrier. Am. J. Physiol. 251, E477-E482.
7. Israili, Z.H. and Dayton, P.G. (1984) Enhancement of xenobiotic elimination: role of intestinal excretion. Drug Metab. Rev. 15, 1123-1159.
8. Oude Elferink, R.P.J., Meijer, D.K.F., Kuipers, F., Jansen, P.L.M., Groen, A.K. and Groothuis, G.M.M. (1995) Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta 1241, 215-268.
9. Kinne, R.K.H. (1991) Selectivity and direction: plasma membranes in renal transport. Am. J. Physiol. 260, F153-F162.
10. Dayton, P.G., Israili, Z.H. and Henderson, J.D. (1983) Elimination of drugs by passive diffusion from blood to intestinal lumen: factors influencing nonbiliary excretion by the intestinal tract. Drug. Metab. Rev. 14, 1193-1206.
11. Mu, J.Y., Israili, Z.H. and Dayton, P.G. (1975) Studies of the disposition and metabolism of mefloquine HCl (WR 142490), a quinolinemethanol antimalarial, in the rat. Drug Metab. Dispos. 3, 198-210.
12. 14C-erythromycin. J. Pharmacol. Exp. Ther. 117, 265-273.
13. Caldwell, J.H., Caldwell, P.B., Murphy, J.W. and Beachler, C.W. (1980) Intestinal secretion of digoxin in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 312, 271-275.
14. Holland, D.R. and Quay, J.F. (1976) Intestinal secretion of erythromycin base. J. Pharm. Sci. 65, 417-419.
15. George, C.F. and Gruchy, B.S. (1979) Elimination of drugs by active intestinal transport. J. Pharm. Pharmacol. 31, 643-644.
16. Lauterbach, F. (1971) Absorption of cardiac glycosides. Acta. Pharmacol. Toxicol. 29 (Suppl. 4), 80.
17. Lauterbach, F. (1975) Resorption und sekretion von arzneis-toffen durch die mukosaepithelien des gastrointestinaltraktes. Arzneim. Forsch. 25, 479-488.
18. Lauterbach, F. (1977) Intestinal secretion on ions and drugs. In: M. Kramer and F. Lauberbach, (Eds.), Intestinal Permeation, Excerpta Medica, Amsterdam, pp. 173-194.
19. Beck, W.T. (1987) The cell biology of multiple drug resistance. Biochem. Pharmacol. 36, 2879-2887.
20. Simon, S.M. and Schindler, M. (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA 91, 3497-3504.
21. Endicott, J.A. and Ling, V. (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58, 137-171.
22. Germann, U.A., Pastan, I. and Gottesman, M.M. (1993) P-glycoproteins: mediators of multidrug resistance. Semin. Cell. Biol. 4, 63-76.
23. Higgins, C.F. (1992) ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. 8, 67-113.
24. Doige, C.A. and Ames, G.F-L. (1993) ATP-dependent transport systems in bacteria and humans: relevance to cystic fibrosis and multidrug resistance. Annu. Rev. Microbiol. 47, 291-319.
25. Wigler, P.W. and Patterson, F.K. (1993) Inhibition of the multidrug resistance efflux pump. Biochim. Biophys. Acta 1154, 173-181.
26. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. and Willingham, M.C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738.
27. Cordon-Cardo, C., O'Brien, J.P., Boccia, J., Casals, D., Bertino, J.R. and Melamed, M.R. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38, 1277-1287.
28. Mukhopadhyay, T., Batsakis, J.G. and Kuo, M.T. (1988) Expression of the mdr (P-glycoprotein) gene in Chinese hamster digestive tracts. J. Natl. Cancer Inst. 80, 269-275.
29. Peters, W.H.M., Boon, C.E.W., Roelofs, H.M.J., Wobbes, T., Nagengast, F.M. and Kremers, P.G. (1992) Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 103, 448-455.
30. 1). J. Pharmacol. Exp. Ther. 263, 840-845.
31. de Lannoy, I.A.M. and Silverman, M. (1992) The mdr1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Commun. 189, 551-557.
32. Bair, C.H., Tang, M.J. and Huang, J.D. (1992) Concentration-dependent exsorption of quinidine in the rat intestine. J. Pharm. Pharmacol. 44, 659-662.
33. Muller, M., Mayer, R., Hero, U. and Keppler, D. (1994) ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. Fed. Eur. Biochem. Soc. Lett. 343, 168-172.
34. Leu, B.L. and Huang, J.D. (1995) Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol. 35, 432-436.
35. Seidenstücker, R. and Lauterbach, F. (1976) Mediation of intestinal absorption of cardiotonic steroids by a secretory transfer mechanism, Naunyn-Schmiedeberg's Arch. Pharmacol. 293 (Suppl.), R45.
36. Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R. and Bertino, J.R. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86, 695-698.
37. Jetté, L., Tétu, B. and Béliveau, R. (1993) High levels of P-glycoprotein detected in isolated brain capillaries. Biochim. Biophys. Acta 1150, 147-154.
38. Schinkel, A.H., Smit, J.J.M., van Tellingen, O., Beijnen, J.H., Wagennar, E., van Deemster, L., Mol, C.A.A.M., van der Valk, M.A., Robanus-Maandag, E.C., te Reile, H.P.J., Berns, A.J.M. and Borst, P. (1994) Disruption of the mouse mdr1 a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502.
39. Ho, N.F.H., Burton, P.S., Conradi, R.A. and Barsuhn, C.L. (1995) A biophysical model of passive and polarized active transport processes in Caco-2 cells: approaches to uncoupling apical and basolateral membrane events in the intact cell. J. Pharm. Sci. 84, 21-27.
40. Saitoh, H. and Aungst, B.J. (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm. Res. 12, 1304-1310.
41. Horio, M., Chin, K.V., Currier, S.J., Goldenberg, S., Williams, C., Pastan, I., Gottesman, M.M. and Handler, J. (1989) Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J. Biol. Chem. 264, 14 880-14 884.
42. Pan, B.F., Dutt, A. and Nelson, J.A. (1994) Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. J. Pharmacol. Exp. Ther. 270, 1-7.
43. Pinto, M., Robine-Leon, S., Appay, M.D., Kedinger, M., Triadou, N., Dussaulx, E., LaCroix, B., Simon-Assman, P., Haffen, K., Fogh, J. and Zweibaum, A. (1983) Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47, 323-330.
44. Zweibaum, A., Laburthe, M., Grasset, E. and Louvard, D. (1991) Use of cultured cell lines in studies of intestinal cell differentiation and function, In: M. Field and R.A. Frizzell (Eds.), Handbook of Physiology, Section 6. The Gastrointestinal System, Vol. IV, Intestinal Absorption and Secretion. Am. Physiol. Society, Bethesda, MD, pp. 223-255.
45. Hidalgo, I.J., Raub, T.J. and Borchardt, R.T. (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96, 736-749.
46. Hilgers, A.R., Conradi, R.A. and Burton, P.S. (1990) Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7, 902-910.
47. Artursson, P. (1990) Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79, 476-482.
48. Wilson, G., Hassan, I.F., Dix, C.J., Williamson, I., Shah, R., Mackay, M. and Artursson, P. (1990) Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J. Control. Rel. 11, 25-40.
49. Peters, W.H.M. and Roelofs, H.M.J. (1992) Biochemical characterisation of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases. Cancer Res. 52, 1886-1890.
50. Kartner, N., Evernden-Porelle, D., Bradley, G. and Ling, V. (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316, 820-823.
51. Wils, P., Phung-Ba, V., Warnery, A., Lechardeur, D., Raeissi, S., Hidalgo, I.J. and Scherman, D. (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol. 48, 1528-1530.
52. Hunter, J., Jepson, M.A., Tsuruo, T., Simmons, N.L. and Hirst, B.H. (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268, 14 991-14 997.
53. Hunter, J., Hirst, B.H. and Simmons, N.L. (1993) Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10, 743-749.
54. Karlsson, J., Kuo, S.M., Ziemniak, J. and Artursson, P. (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110, 1009-1016.
55. Audus, K.L. and Borchardt, R.T. (1986) Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm. Res. 3, 81-87.
56. Takakura, Y., Audus, K.L. and Borchardt, R.T. (1991) Blood-brain barrier: transport studies in isolated brain capil laries and in cultured brain endothelial cells. Adv. Pharmacol. 22, 137-165.
57. Tsuji, A., Terasaki, T., Takabatake, Y., Tenda, Y., Tamai, I., Yamashima, T., Moritani, S., Tsuruo, T. and Yamashita, J. (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51, 1427-1437.
58. Ohnishi, T., Tamai, I., Sakanaka, K., Sakata, A., Yamashima, T., Yamashita, J. and Tsuji, A. (1995) In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem. Pharmacol. 49, 1541-1544.
59. Tatsuta, T., Naito, M., Oh-hara, T., Sugawara, I. and Tsuruo, T. (1992) Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267, 20 383-20 391.
60. Sharom, F.J., DiDiodato, G., Yu, X. and Ashbourne, K.J.D. (1995) Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J. Biol. Chem. 270, 10 334-10 341.
61. Sharma, R.C., Inoue, S., Roitelman, J., Schimke, R.T. and Simoni, R.D. (1992) Peptide transport by the multidrug resistance pump. J. Biol. Chem. 267, 5731-5734.
62. Naito, M., Tsuge, H., Kuroko, C., Koyama, T., Tomida, A., Tatsuta, T., Heike, Y. and Tsuruo, T. (1993) Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J. Natl. Cancer Inst. 85, 311-316.
63. Toppmeyer, D.L., Slapak, C.A., Croop, J. and Kufe, D.W. (1994) Role of P-glycoprotein in dolastatin 10 resistance. Biochem. Pharmacol. 48, 609-612.
64. Sarkadi, B., Müller, M., Homolya, L., Holló, Z., Sepródi, J., Germann, U.A., Gottesman, M.M., Price, E.M. and Boucher, R.C. (1994) Interaction of bioactive hydrophobic peptides with the human multidrug transporter. Fed. Am. Sos. Exp. Biol. J. 8, 766-770.
65. Burton, P.S., Conradi, R.A., Hilgers, A.R. and Ho, N.F.H. (1993) Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190, 760-766.
66. Nerurkar, M.M., Burton, P.S. and Borchardt, R.T. (1994) Use of surfactants to enhance the intestinal permeability of peptides by inhibition of P-glycoprotein. Pharm. Res. 11, S251.
67. Nerurkar, M.M., Burton, P.S. and Borchardt, R.T. (1996) The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13, 528-534.
68. Augustijns, P.F., Bradshaw, T.P., Can, L.S.L., Hendren, R.W. and Thakker, D.R. (1993) Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197, 360-365.
69. A with P-glycoprotein in human intestinal epithelial cells. Eur. J. Pharmacol. 288, 187-192.
70. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993) Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268, 6077-6080.
71. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R. (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267, 24 248-24 252.
72. Tsuji, A., Tamai, I., Sakata, A., Tenda, Y. and Terasaki, T. (1993) Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46, 1096-1099.
73. Shirai, A., Naito, M., Tatsuta, T., Dong, J., Hanaoka, K., Mikami, K., Oh-hara, T. and Tsuruo, T. (1994) Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. Biophys. Acta 1222, 400-404.
74. Sakata, A., Tamai, I., Kawazu, K., Deguchi, Y., Ohnishi, T., Saheki, A. and Tsuji, A. (1994) In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48, 1989-1992.
75. Chikhale, E.G., Burton, P.S. and Borchardt, R.T. (1995) The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J. Pharmacol. Exp. Ther. 273, 298-303.
76. Burton, P.S., Conradi, R.A., Ho, N.F.H., Hilgers, A.R. and Borchardt, R.T. (1996) How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. in press.
77. Nerurkar, M.M., Burton, P.S., Ho, N.F.H. and Borchardt, R.T. (1995) Use of surfactants to enhance the intestinal permeability of peptides by inhibition of an apically polarized efflux system. Pharm. Res. 12, S303.
78. Ramon, J., Dautery, S., Farinoti, R., Carbon, C. and Rubinstein, E. (1994) Intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents. Chemother. 38, 757-780.
79. Sorgel, F., Naber, K.G., Jaehde, U., Reiter, A., Seelman, R. and Sigl, G. (1989) Gastrointestinal secretion of ciprofloxacin. Am. J. Med. 87, 63S-65S.
80. Griffiths, N.M., Hirst, B.H. and Simmons, N.L. (1993) Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br. J. Pharmacol. 108, 575-576.
81. Burton, P.S., Conradi, R.A., Hilgers, A.R. and Ho, N.F.H. (1994) Polarized efflux pathways for peptides in Caco-2 cells: evidence for at least two distinct systems. Pharm. Res. 11, S252.
82. Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427.
83. Stein. W.D., Cardarelli, C., Pastan, I. and Gottesman, M.M. (1994) Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol. Pharmacol. 45, 763-772.
84. Hartl, F.U. and Martin, J. (1995) Molecular chaperones in cellular protein folding. Curr. Opin. Struct. Biol. 5, 92-102.
85. Loo, T.W. and Clarke, D.M. (1993) Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 268, 3143-3149.
86. Devine, S.E. and Melera, P.W. (1994) Diversity of multidrug resistance in mammalian cells. J. Biol. Chem. 269, 6133-6139.
87. Devine, S.E., Ling, V. and Melara, P.W. (1992) Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc. Natl. Acad. Sci. USA 89, 4564-4568.
88. Zhang, J.T. and Ling, V. (1995) Involvement of cytoplasmic factors regulating the membrane orientation of P-glycoprotein sequences. Biochemistry 34, 9159-9165.
89. Bates, S.E., Currier, S.J., Alvarez, M. and Fojo, A.T. (1992) Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31, 6366-6372.
90. Herzog, C.E., Tsokos, M., Bates, S.E. and Fojo, A.T. (1993) Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J. Biol. Chem. 268, 2946-2952.
91. Chin, K.-V., Tanaka, S., Darlington, G., Pastan, I. and Gottesman, M.M. (1990) Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J. Biol. Chem. 265, 221-226.
92. Krishnamachary, N. and Center, M.S. (1993) The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53, 3658-3661.
93. Zaman, G.J.R., Flens, M.J., van Leusden, M.R., de Haas, M., Mülder, H.S., Lankelma, J., Pinedo, H.M., Scheper, R.J., Baas, F., Broxterman, H.J. and Borst, P. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 91, 8822-8826
94. Mayer, R., Kartenbeck, J., Büchler, M., Jedlitschky, G., Leier, I. and Keppler, D. (1995) Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell Biol. 131, 137-150.
95. Thomas, G.A., Barrand, M.A., Steward, S., Rabbitts, P.H., Williams, E.D. and Twentyman, P.R. (1994) Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur. J. Cancer 30A, 1705-1709.
96. 4 and structurally related compounds. J. Biol. Chem. 269, 27 807-27 810.
97. Zaman, G.J.R., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R.P.J., Baas, F. and Borst, P. (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 92, 7690-7694.
98. Versantvoort, C.H.M., Broxterman, H.J., Lankelma, J., Feller, N. and Pinedo, H.M. (1994) Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 48, 1129-1136.
99. 1 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53, 1475-1479.
100. Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A., Slovak, M.L., Pinedo, H.M., Meijer, C.J.L.M., Clevers, H.C. and Scheper, R.J. (1995) The drug resistance-related protein LRP is the major human vault protein. Nat. Med. 1, 578-582.
101. Gründemann, D., Gorboulev, V., Gambaryan, S., Veyhl, M. and Koepsell, H. (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372, 549-552.
102. van Kalken, C.K., Broxterman, H.J., Pinedo, H.M., Feller, N., Dekker, H., Lankelma, J. and Giaccone, G. (1993) Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 67, 284-289.
103. Smit, J.J.M., Schinkel, A.H., Oude Elferink, R.P.J., Groen, A.K., Wagenaar, E., van Deemter, L., Mol, C.A.A.M., Ottenhoff, R., van der Lugt, N.M.T., van Roon, M.A., van der Valk, M.A., Offerhaus, G.J.A., Berns, A.J.M. and Borst, P. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75, 451-462.
104. Buschman, E. and Gros, P. (1991) Functional analysis of chimeric genes obtained by exchanging homologous domains of the mouse mdr1 and mdr2 genes. Mol. Cell. Biol. 11, 595-603.
105. Borst, P., Schinkel, A.H., Smit, J.J.M., Wagenaar, E., Van Deemter, L., Smith, A.J., Eijdems, E.W.H.M., Baas, F. and Zaman, G.J.R. (1993) Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther. 60, 289-299.
106. Thorgeirsson, S.S., Silverman, J.A., Gant, T.W. and Marino, P.A. (1991) Multidrug resistance gene family and chemical carcinogens. Pharmacol. Ther. 49, 283-292.
107. Lum, B.L. and Gosland, M.P. (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 9, 319-336.
108. Lum, B.L., Kaubisch, S., Yahanda, A.M., Adler, K.M., Jew, L., Ehsan, M.N., Brophy, N.A., Halsey, J., Gosland, M.P. and Sikic, B.I. (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10, 1635-1642.
109. Fisher, G.A., Bartlett, M.L., Lum, B.L., Brophy, N.A., Duran, G.E., Ehsan, M.N., Halsey, J. and Sikic, B.I. (1994) Phase I trial of taxol with high dose cyclosporin as a modulator of multidrug resistance. Proc. Am. Soc. Clin. Oncol. 13, 144.
110. Kerr, D.J., Graham, J., Cummings, J., Morrison, J.G., Thompson, G.G., Brodie, M.J. and Kaye, S.B. (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18, 239-242.
111. Barbui, T., Rambaldi, A., Parenzan, L., Zucchelli, M., Perico, N. and Remuzzi, G. (1992) Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet 339, 1421.
112. Berkower, C. and Michaelis, S. (1991) Mutational analysis of the yeast a-factor transporter STE6, a member of the ATP binding cassette (ABC) protein superfamily. EMBO J. 10, 3777-3785.
113. Conradi, R.A., Hilgers, A.R., Ho, N.F.H. and Burton, P.S. (1991) The influence of peptide structure on transport across Caco-2 cells. Pharm. Res. 8, 1453-1460.
114. Conradi, R.A., Hilgers, A.R., Ho, N.F.H. and Burton, P.S. (1992) The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm. Res. 9, 435-439.